[Pancreatic cancer]
- PMID: 21129675
- DOI: 10.1016/S1278-3218(10)70012-3
[Pancreatic cancer]
Abstract
About 7200 new cases of pancreatic adenocarcinomas are diagnosed each year in France. At the time of diagnosis, an efficient carcinologic surgery will not be possible for nearly 80% of patients, in relation to loco-regional extension or metastatic dissemination. After surgical resection, the median survival of resected patients ranges from 12 to 20 months, with a high rate of relapses. Currently, the use of radiotherapy for patients with pancreatic cancer is controversial. In adjuvant setting, the standard treatment is six months of chemotherapy with FUFOL or gemcitabine. Chemoradiation (CRT) may improve the survival of patients with incompletely resected tumors (R1). This must be validated in a prospective trial. Neoadjuvant CRT is a promising treatment but always under evaluation. For the treatment of patients with locally advanced tumors, there is not a standart treatment. A strategy of initial chemotherapy followed by CRT for non progressive patients is under evaluation. Whereas in the first trials of CRT large fields were used, the current trend is to reduce the treated volumes to improve tolerance. The delineation of target volumes has been improved by the use of simulation CT. The aims of this work are to precise the radio-anatomical particularities, the pattern of spread of pancreatic cancer and the principles of 3D conformal radiotherapy illustrated with a clinical case.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.
Similar articles
-
[Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma in 2006].Bull Cancer. 2007 Jan;94(1):72-80. Bull Cancer. 2007. PMID: 17237007 Review. French.
-
[Is there still a place for radiotherapy for the treatment of pancreatic cancers?].Presse Med. 2010 Jun;39(6):645-52. doi: 10.1016/j.lpm.2009.09.018. Epub 2009 Nov 20. Presse Med. 2010. PMID: 19931999 French.
-
Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.Gan To Kagaku Ryoho. 1999 Jan;26(1):10-40. Gan To Kagaku Ryoho. 1999. PMID: 9987495 Review.
-
Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis.Ann Surg Oncol. 2009 Aug;16(8):2116-22. doi: 10.1245/s10434-009-0498-1. Epub 2009 May 13. Ann Surg Oncol. 2009. PMID: 19437078
-
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.J Clin Oncol. 2007 Jan 20;25(3):326-31. doi: 10.1200/JCO.2006.07.5663. J Clin Oncol. 2007. PMID: 17235048
Cited by
-
Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.Am J Surg Pathol. 2012 Apr;36(4):552-9. doi: 10.1097/PAS.0b013e318240c1c0. Am J Surg Pathol. 2012. PMID: 22301496 Free PMC article.
-
Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma.Cancer Sci. 2019 Apr;110(4):1491-1502. doi: 10.1111/cas.13975. Epub 2019 Mar 19. Cancer Sci. 2019. PMID: 30776178 Free PMC article.
-
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.Cancer. 2012 Jun 15;118(12):3182-90. doi: 10.1002/cncr.26651. Epub 2011 Oct 25. Cancer. 2012. PMID: 22028089 Free PMC article.
-
Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.Am J Surg Pathol. 2012 Mar;36(3):409-17. doi: 10.1097/PAS.0b013e31824104c5. Am J Surg Pathol. 2012. PMID: 22301497 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials